206 related articles for article (PubMed ID: 8927035)
1. Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents.
Crans DC; Mahroof-Tahir M; Keramidas AD
Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):17-24. PubMed ID: 8927035
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic, Chemical, and Physical Properties of Organic Vanadates as Presumed Transition-State Inhibitors for Phosphatases.
Crans DC
J Org Chem; 2015 Dec; 80(24):11899-915. PubMed ID: 26544762
[TBL] [Abstract][Full Text] [Related]
3. Is vanadate reduced by thiols under biological conditions? Changing the redox potential of V(V)/V(IV) by complexation in aqueous solution.
Crans DC; Zhang B; Gaidamauskas E; Keramidas AD; Willsky GR; Roberts CR
Inorg Chem; 2010 May; 49(9):4245-56. PubMed ID: 20359175
[TBL] [Abstract][Full Text] [Related]
4. Chemistry and insulin-like properties of vanadium(IV) and vanadium(V) compounds.
Crans DC
J Inorg Biochem; 2000 May; 80(1-2):123-31. PubMed ID: 10885472
[TBL] [Abstract][Full Text] [Related]
5. [Insulin-mimetic property of vanadium compounds].
Korbecki J; Baranowska-Bosiacka I; Gutowska I; Chlubek D
Postepy Biochem; 2016; 62(1):60-65. PubMed ID: 28132446
[TBL] [Abstract][Full Text] [Related]
6. Aqueous chemistry of the vanadium(III) (V(III)) and the V(III)-dipicolinate systems and a comparison of the effect of three oxidation states of vanadium compounds on diabetic hyperglycemia in rats.
Buglyó P; Crans DC; Nagy EM; Lindo RL; Yang L; Smee JJ; Jin W; Chi LH; Godzala Iii ME; Willsky GR
Inorg Chem; 2005 Jul; 44(15):5416-27. PubMed ID: 16022540
[TBL] [Abstract][Full Text] [Related]
7. Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review.
Scior T; Guevara-García A; Bernard P; Do QT; Domeyer D; Laufer S
Mini Rev Med Chem; 2005 Nov; 5(11):995-1008. PubMed ID: 16307529
[TBL] [Abstract][Full Text] [Related]
8. Vanadium Compounds with Antidiabetic Potential.
Amaral LMPF; Moniz T; Silva AMN; Rangel M
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958659
[TBL] [Abstract][Full Text] [Related]
9. Chloro-substituted dipicolinate vanadium complexes: synthesis, solution, solid-state, and insulin-enhancing properties.
Smee JJ; Epps JA; Ooms K; Bolte SE; Polenova T; Baruah B; Yang L; Ding W; Li M; Willsky GR; la Cour A; Anderson OP; Crans DC
J Inorg Biochem; 2009 Apr; 103(4):575-84. PubMed ID: 19201030
[TBL] [Abstract][Full Text] [Related]
10. The chemistry of peroxovanadium compounds relevant to insulin mimesis.
Shaver A; Ng JB; Hall DA; Posner BI
Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):5-15. PubMed ID: 8927048
[TBL] [Abstract][Full Text] [Related]
11. Insulin-mimetic action of vanadium compounds on osteoblast-like cells in culture.
Etcheverry SB; Crans DC; Keramidas AD; Cortizo AM
Arch Biochem Biophys; 1997 Feb; 338(1):7-14. PubMed ID: 9015381
[TBL] [Abstract][Full Text] [Related]
12. In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds.
Rehder D; Costa Pessoa J; Geraldes CF; Castro MC; Kabanos T; Kiss T; Meier B; Micera G; Pettersson L; Rangel M; Salifoglou A; Turel I; Wang D
J Biol Inorg Chem; 2002 Apr; 7(4-5):384-96. PubMed ID: 11941496
[TBL] [Abstract][Full Text] [Related]
13. Sarcoplasmic reticulum calcium ATPase is inhibited by organic vanadium coordination compounds: pyridine-2,6-dicarboxylatodioxovanadium(V), BMOV, and an amavadine analogue.
Aureliano M; Henao F; Tiago T; Duarte RO; Moura JJ; Baruah B; Crans DC
Inorg Chem; 2008 Jul; 47(13):5677-84. PubMed ID: 18510311
[TBL] [Abstract][Full Text] [Related]
14. The permeability and cytotoxicity of insulin-mimetic vanadium (III,IV,V)-dipicolinate complexes.
Zhang Y; Yang XD; Wang K; Crans DC
J Inorg Biochem; 2006 Jan; 100(1):80-7. PubMed ID: 16321441
[TBL] [Abstract][Full Text] [Related]
15. New diketone based vanadium complexes as insulin mimetics.
Sheela A; Roopan SM; Vijayaraghavan R
Eur J Med Chem; 2008 Oct; 43(10):2206-10. PubMed ID: 18336956
[TBL] [Abstract][Full Text] [Related]
16. [The vanadium compounds: chemistry, synthesis, insulinomimetic properties].
Fedorova EV; Buriakina AV; Vorob'eva NM; Baranova NI
Biomed Khim; 2014; 60(4):416-29. PubMed ID: 25249525
[TBL] [Abstract][Full Text] [Related]
17. Structural and redox requirements for the action of anti-diabetic vanadium compounds.
Yoshikawa Y; Sakurai H; Crans DC; Micera G; Garribba E
Dalton Trans; 2014 May; 43(19):6965-72. PubMed ID: 24668346
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
Thompson KH; Liboiron BD; Sun Y; Bellman KD; Setyawati IA; Patrick BO; Karunaratne V; Rawji G; Wheeler J; Sutton K; Bhanot S; Cassidy C; McNeill JH; Yuen VG; Orvig C
J Biol Inorg Chem; 2003 Jan; 8(1-2):66-74. PubMed ID: 12459900
[TBL] [Abstract][Full Text] [Related]
19. Maltol complexes of vanadium (IV) and (V) regulate in vitro alkaline phosphatase activity and osteoblast-like cell growth.
Barrio DA; Braziunas MD; Etcheverry SB; Cortizo AM
J Trace Elem Med Biol; 1997 Jun; 11(2):110-5. PubMed ID: 9285892
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
